Drug name - Evomela

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9200088 ACROTECH Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same Jun, 2030

(7 years from now)

US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Jan, 2034

(11 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.